BI
MACK

BVF Inc’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

BVF Inc’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-917,579
Closed -$2.79M – 58
2018
Q4 		$2.79M Sell
917,579
-493,978
-35% -$1.71M 0.36% 45
2018
Q3 		$5.92M Hold
1,411,557
– – 0.52% 43
2018
Q2 		$5.45M Buy
+1,411,557
New +$9.37M 0.53% 41

Other funds holding MACK

NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
2L
22NW LP Seattle, Washington $105M AUM 38.33% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
WSL
Western Standard LLC Los Angeles, California $295M AUM 40.98% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WIM
Wittenberg Investment Management Carlisle, Massachusetts $292M AUM 36.12% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

BVF Inc's MACK Position: Q1 2019 in Review

BVF Inc sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q1 2019, closing a stake of 917,579 shares — an estimated $2.79M sold.

BVF Inc first reported a position in MACK in Q2 2018 and held it in 3 quarters. The position peaked at $5.92M in Q3 2018. 54 funds tracked by Wall St. Rank hold MACK as of Q1 2019.

  • BVF Inc reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q1 2019 after selling out during the quarter.
  • BVF Inc sold 917,579 Merrimack Pharmaceuticals, Inc. shares in Q1 2019, an estimated $2.79M.
  • BVF Inc first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2018 and held it in 3 quarters.
  • BVF Inc's Merrimack Pharmaceuticals, Inc. position peaked at $5.92M in Q3 2018.
  • 54 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q1 2019.

Based on BVF Inc's 13F filing for Q1 2019, filed 15 May 2019.